证券代码：605199 证券简称：ST 葫芦娃 公告编号：2025-064 海南葫芦娃药业集团股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ??会议召开时间：2025 年 9 月 5 日(星期五) 下午 15:00-16:00 ? 会议召开地点：上海证券交易所上证路演中心（网址：https://roadshow.sseinfo. com/） ? 会议召开方式：上证路演中心网络互动 ??投资者可于 2025 年 8 月 29 日(星期五) 至 9 月 4 日(星期四)16:00 前登录上证路演 中心网站首页点击"提问预征集"栏目或通过公司邮箱 huluwa@huluwayaoye.com 进行 提问。公司将在说明会上对投资者普遍关注的问题进行回答。 海南葫芦娃药业集团股份有限公司（以下简称"公司"）已于 2025 年 8 月 29 日发 布公司 2025 年半年度报告，为便于广大投资者更全面深入地了解公司 2025 年半年度的 经营成果、财务状况，公司 ...

证券代码：605199 证券简称：ST 葫芦娃 公告编号：2025-060 （五）本次董事会会议由董事长刘景萍女士主持，公司全体监事、高级管理人员列 席会议。 二、董事会会议审议情况 （一）审议通过了《关于公司 2025 年半年度报告及其摘要的议案》 海南葫芦娃药业集团股份有限公司 第三届董事会第六次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 （一）海南葫芦娃药业集团股份有限公司（以下简称"公司"）第三届董事会第六 次会议的召开符合《公司法》《公司章程》和《董事会议事规则》的有关规定，会议合 法有效。 （二）会议通知和材料于 2025 年 8 月 18 日以邮件方式发出。 （三）会议于 2025 年 8 月 29 日在海南省海口市秀英区安读一路 30 号公司会议室 以现场结合通讯方式召开。 （四）公司董事会会议应出席董事 7 人，实际出席董事 7 人（其中以通讯表决方式 出席会议的董事 2 人）。 具体内容详见公司于上海证券交易所网站（www.sse.com.cn）同日披露的《海南葫 ...

Summary of Key Points Core Viewpoint The report provides an overview of the fundraising activities and the utilization of raised funds by Hainan Huluwa Pharmaceutical Group Co., Ltd. for the first half of 2025, highlighting the total amount raised, expenses incurred, and the allocation of funds to various projects. Fundraising Basic Situation - The company raised a total of RMB 208,119,000.00 by issuing 40,100,000 shares at RMB 5.19 per share, with net proceeds amounting to RMB 173,119,000.00 after deducting underwriting fees of RMB 35,000,000.00 [1][2]. - The funds were deposited into a regulatory account managed by the lead underwriter, CITIC Securities Co., Ltd. [1]. Fundraising Usage and Balance - As of June 30, 2025, the total amount of raised funds was RMB 208,119,000.00, with total expenses of RMB 57,079,347.77, resulting in a net amount of RMB 151,039,652.23 [2]. - The remaining balance of the raised funds at the end of the period was RMB 11,878,482.50 after accounting for various expenditures and interest income [2][4]. Fund Management and Storage - The company established a dedicated account for the management of raised funds, adhering to relevant regulations and guidelines to ensure proper usage and protection of investor interests [2][3]. - A tripartite supervision agreement was signed with the banks and the underwriter to clarify the rights and obligations of all parties involved [2][3]. Project Adjustments and Fund Allocation - The company adjusted the implementation of the "Marketing System Construction and Brand Promotion Project" to be managed by its wholly-owned subsidiary, Hainan Huluwa Pharmaceutical Co., Ltd. [3]. - The company decided to reallocate funds from the "Pediatric Drug Research Project" to other urgent drug research projects due to delays in the original project [10][11]. Financial Performance and Future Outlook - The company reported that the fundraising projects do not directly generate economic benefits, making it challenging to assess their individual performance [6][11]. - The long-term benefits of the drug research projects are expected to enhance the company's core competitiveness and market presence [6][7]. Compliance and Disclosure - The company confirmed compliance with all relevant laws and regulations regarding the use of raised funds and timely disclosure of information [12][13]. - There were no violations in the use of raised funds, and all disclosed information accurately reflects the company's financial activities [12].

证券代码：605199 证券简称：ST 葫芦娃 公告编号：2025-061 海南葫芦娃药业集团股份有限公司 第三届监事会第六次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、 监事会会议召开情况 （一）海南葫芦娃药业集团股份有限公司（以下简称"公司"）第三届监事会第六次 会议的召开符合《公司法》《公司章程》和《监事会议事规则》的有关规定，会议合法 有效。 （五）本次会议由监事会主席徐鹏先生主持召开，董事会秘书王清涛先生、证券事务 代表王海燕女士列席会议。 二、监事会会议审议情况 （一）审议通过了《关于公司 2025 年半年度报告及其摘要的议案》 具体内容详见公司于上海证券交易所网站（www.sse.com.cn）同日披露的《海南葫 芦娃药业集团股份有限公司 2025 年半年度报告及摘要》。 公司监事会根据《证券法》和《上海证券交易所股票上市规则》等相关规定和要求， 对董事会编制的公司 2025 年半年度报告进行了严格的审核。监事会认为： （1）公司 2025 年半年度报告的编制和审议程序符合法律、法规及《公司 ...

Core Viewpoint - The report indicates a significant decline in the financial performance of Hainan Huluwa Pharmaceutical Group Co., Ltd. for the first half of 2025, with substantial decreases in revenue and profit compared to the previous year [1][5]. Financial Summary - Total assets at the end of the reporting period amounted to CNY 2,913.61 million, a decrease of 1.72% from the previous year [1]. - Operating revenue for the period was CNY 507.67 million, representing a decline of 42.89% compared to CNY 888.95 million in the same period last year [1]. - Total profit for the period was CNY 8.18 million, down 83.71% from CNY 50.20 million in the previous year [1]. - The net profit attributable to shareholders was CNY -18.78 million, compared to a profit of CNY 4.53 million in the same period last year [1]. - The weighted average return on net assets decreased by 3.62 percentage points [1]. Shareholder Information - The largest shareholder, Hainan Huluwa Investment Development Co., Ltd., holds 41.76% of the shares, with 167.08 million shares pledged [2]. - Other significant shareholders include Zhejiang Fuwang Juder Health Development Co., Ltd. with 14.38% and Hangzhou Zhongjia Rui Management Partnership with 6.88% [2]. Important Matters - The company faced a risk warning due to a negative internal control audit report issued by the accounting firm, which led to the implementation of risk warnings on April 30, 2025 [3][5]. - In response to the audit findings, the company has initiated several corrective measures, including the establishment of a special rectification team led by the chairman to conduct comprehensive self-inspections [6]. - The company is enhancing its internal control management and compliance awareness through various initiatives, including risk assessments of new contracts and improved communication with external auditors [6].

Core Viewpoint - ST Huhuwawa reported a significant decline in both revenue and profit for the first half of 2025, indicating financial distress and operational challenges [1][2]. Financial Performance - The company's revenue for the first half of 2025 was 508 million yuan, a year-on-year decrease of 42.89% [1]. - The net profit attributable to shareholders was 2.41 million yuan, down 94.14% year-on-year [1]. - The non-recurring net profit attributable to shareholders was -18.78 million yuan, a decline of 514.52% year-on-year [1]. - Basic earnings per share stood at 0.01 yuan [2]. Profitability Metrics - The gross profit margin for the first half of 2025 was 43.28%, down 8.06 percentage points year-on-year [2]. - The net profit margin was 0.89%, a decrease of 3.97 percentage points compared to the same period last year [2]. - In Q2 2025, the gross profit margin was 51.30%, down 2.46 percentage points year-on-year but up 12.09 percentage points quarter-on-quarter [2]. - The net profit margin for Q2 2025 was -11.69%, a decline of 15.19 percentage points year-on-year and down 18.96 percentage points from the previous quarter [2]. Expense Analysis - Total operating expenses for the first half of 2025 were 206 million yuan, a reduction of 225 million yuan year-on-year [2]. - The expense ratio was 40.67%, down 7.89 percentage points year-on-year [2]. - Sales expenses decreased by 60.25% year-on-year, while management expenses increased by 15.96% [2]. - R&D expenses fell by 80.69%, and financial expenses rose by 77.74% [2]. Shareholder Information - As of the end of the first half of 2025, the total number of shareholders was 31,600, a decrease of 11,900 or 27.30% from the previous quarter [2]. - The average market value of shares held per shareholder decreased from 136,400 yuan to 114,900 yuan, a decline of 15.76% [2]. Company Overview - ST Huhuwawa, established on June 22, 2005, is located in Haikou, Hainan Province, and was listed on July 10, 2020 [3]. - The company's main business includes the research, production, and sales of traditional Chinese medicine and chemical drugs [3]. - The revenue composition includes respiratory drugs (58.92%), digestive system drugs (21.43%), systemic anti-infection drugs (9.75%), other drugs (5.67%), and raw materials (4.22%) [3]. - The company belongs to the pharmaceutical and biological industry, specifically in the traditional Chinese medicine sector [3].

证券代码：605199 证券简称：ST 葫芦娃 公告编号：2025-062 海南葫芦娃药业集团股份有限公司 关于 2025 年半年度募集资金存放与使用情况的专项报告 | 项目 | 金额（元） | | --- | --- | | 减：以募集资金置换预先投入自筹资金的金额 | 13,914,870.00 | | （注） | | | 减：以前年度募集资金直接投入募投项目金额 | 126,091,679.96 | | 加：以前年度累计利息收入扣除手续费金额 | 930,973.35 | | 募集资金年初余额 | 11,964,075.62 | | 减：本年度募集资金直接投入募投项目金额 | 91,109.60 | | 加：本年度利息收入扣除手续费金额 | 5,516.48 | | 募集资金期末余额 | 11,878,482.50 | 注：本公司于 2020 年 8 月 27 日召开第二届董事会第四次会议，审议通过了《关 于公司使用募集资金置换预先投入募投项目的自筹资金的议案》，同意公司合计使用募 集资金人民币 13,914,870.00 元置换预先投入募投项目的自筹资金。天健会计师事务所 （特殊普通合伙）对该事项进行 ...

证券代码：605199 证券简称：ST 葫芦娃 公告编号：2025-064 海南葫芦娃药业集团股份有限公司 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可于 2025 年 8 月 29 日(星期五) 至 9 月 4 日(星期四)16:00 前登录上证路演 中心网站首页点击"提问预征集"栏目或通过公司邮箱 huluwa@huluwayaoye.com 进行 提问。公司将在说明会上对投资者普遍关注的问题进行回答。 （二） 会议召开地点：上海证券交易所上证路演中心（网址： https://roadshow.sseinfo.com/） 海南葫芦娃药业集团股份有限公司（以下简称"公司"）已于 2025 年 8 月 29 日发 布公司 2025 年半年度报告，为便于广大投资者更全面深入地了解公司 2025 年半年度的 经营成果、财务状况，公司计划于 2025 年 9 月 5 日（星期五）下午 15:00-16:00 举行 2025 年半年度业绩说明会，就投资者关心的问 ...

证券代码：605199 证券简称：ST 葫芦娃 公告编号：2025-061 海南葫芦娃药业集团股份有限公司 第三届监事会第六次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、 监事会会议召开情况 具体内容详见公司于上海证券交易所网站（www.sse.com.cn）同日披露的《海南葫 芦娃药业集团股份有限公司 2025 年半年度报告及摘要》。 公司监事会根据《证券法》和《上海证券交易所股票上市规则》等相关规定和要求， 对董事会编制的公司 2025 年半年度报告进行了严格的审核。监事会认为： （1）公司 2025 年半年度报告的编制和审议程序符合法律、法规及《公司章程》的 有关规定。 （2）公司 2025 年半年度报告的内容和格式符合中国证监会和上海证券交易所的有 关规定，所披露的信息真实、完整地反映了公司 2025 年半年度的经营管理和财务状况 等事项。 （一）海南葫芦娃药业集团股份有限公司（以下简称"公司"）第三届监事会第六次 会议的召开符合《公司法》《公司章程》和《监事会议事规则》的有关规定，会议合法 有效 ...

证券代码：605199 证券简称：ST 葫芦娃 公告编号：2025-060 海南葫芦娃药业集团股份有限公司 第三届董事会第六次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 （四）公司董事会会议应出席董事 7 人，实际出席董事 7 人（其中以通讯表决方式 出席会议的董事 2 人）。 （五）本次董事会会议由董事长刘景萍女士主持，公司全体监事、高级管理人员列 席会议。 二、董事会会议审议情况 （一）审议通过了《关于公司 2025 年半年度报告及其摘要的议案》 具体内容详见公司于上海证券交易所网站（www.sse.com.cn）同日披露的《海南葫 芦娃药业集团股份有限公司 2025 年半年度报告及摘要》。 表决结果：同意 7 票，弃权 0 票，反对 0 票。 本议案已经公司董事会审计委员会审议通过并同意提交公司董事会审议。 （二）审议通过了《关于公司 2025 年半年度募集资金存放与使用情况专项报告的 议案》 （一）海南葫芦娃药业集团股份有限公司（以下简称"公司"）第三届董事会第六 次会议的召开 ...